Compare · LLY vs QURE
LLY vs QURE
Side-by-side comparison of Eli Lilly and Company (LLY) and uniQure N.V. (QURE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and QURE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.09T, about 328.9x QURE ($3.32B).
- Over the past year, LLY is up 57.8% and QURE is up 181.4% - QURE leads by 123.6 points.
- LLY has been more active in the news (16 items in the past 4 weeks vs 2 for QURE).
- LLY has more recent analyst coverage (25 ratings vs 24 for QURE).
- Company
- Eli Lilly and Company
- uniQure N.V.
- Price
- $1159.75+0.10%
- $47.85-1.58%
- Market cap
- $1.09T
- $3.32B
- 1M return
- +3.44%
- +8.50%
- 1Y return
- +57.83%
- +181.42%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 16
- 2
- Recent ratings
- 25
- 24
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
uniQure N.V.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Latest LLY
- Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
- Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases
- FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
- Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,004 units (SEC Form 4)
- Director Luciano Juan R was granted 13 shares, increasing direct ownership by 0.08% to 16,918 units (SEC Form 4)
- Director Fyrwald J Erik was granted 8 shares, increasing direct ownership by 0.01% to 75,418 units (SEC Form 4)
- Director Alvarez Ralph was granted 10 shares, increasing direct ownership by 0.02% to 55,745 units (SEC Form 4)
Latest QURE
- Amendment: SEC Form SCHEDULE 13G/A filed by uniQure N.V.
- SEC Form SCHEDULE 13G filed by uniQure N.V.
- uniQure upgraded by Wolfe Research with a new price target
- SEC Form S-8 filed by uniQure N.V.
- SEC Form 10-Q filed by uniQure N.V.
- uniQure N.V. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
- uniQure to Announce Second Quarter 2026 Financial Results
- SEC Form SCHEDULE 13G filed by uniQure N.V.
- CEO, Managing Director Kapusta Matthew C exercised 21,082 units of Ordinary Shares at a strike of $19.39 and sold $952,051 worth of Ordinary Shares (21,082 units at $45.16) as part of a pre-agreed trading plan (SEC Form 4)